---
title: "Jazz Pharmaceuticals plc (JAZZ.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/JAZZ.US.md"
symbol: "JAZZ.US"
name: "Jazz Pharmaceuticals plc"
industry: "Pharmaceuticals"
datetime: "2026-05-20T09:56:22.276Z"
locales:
  - [en](https://longbridge.com/en/quote/JAZZ.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/JAZZ.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/JAZZ.US.md)
---

# Jazz Pharmaceuticals plc (JAZZ.US)

## Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.jazzpharma.com](https://www.jazzpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.49)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 51 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.20% |  |
| Net Profit YoY | -93.89% |  |
| P/B Ratio | 3.29 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14898282609.00 |  |
| Revenue | 4438686000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.68% | D |
| Profit Margin | 0.66% | C |
| Gross Margin | 90.96% | A |
| Revenue YoY | 9.20% | B |
| Net Profit YoY | -93.89% | E |
| Total Assets YoY | 2.82% | C |
| Net Assets YoY | 8.56% | B |
| Cash Flow Margin | 4529.99% | A |
| OCF YoY | 9.20% | B |
| Turnover | 0.38 | C |
| Gearing Ratio | 61.78% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jazz Pharmaceuticals plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.20%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-93.89%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.29",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14898282609.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4438686000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.68%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.66%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "90.96%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.20%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-93.89%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.82%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.56%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "4529.99%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "9.20%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "61.78%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 505.85 | 58/190 | 14.73 | 14.00 | 13.69 |
| PB | 3.29 | 123/190 | 2.66 | 2.46 | 1.70 |
| PS (TTM) | 3.36 | 84/190 | 2.64 | 2.35 | 1.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 59% |
| Overweight | 6 | 35% |
| Underweight | 1 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 237.45 |
| Highest Target | 275.00 |
| Lowest Target | 188.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/JAZZ.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/JAZZ.US/norm.md)
- [Related News](https://longbridge.com/en/quote/JAZZ.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/JAZZ.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**